NCT05820191 is a Phase 2 clinical trial of Amyvid, Intravenous Solution in Glioblastoma, sponsored by Universidad Central del Caribe.

Who is sponsoring NCT05820191?

NCT05820191 is sponsored by Universidad Central del Caribe.

What drugs are being tested in NCT05820191?

Interventions in NCT05820191: Amyvid, Intravenous Solution.

What condition does NCT05820191 study?

NCT05820191 studies Glioblastoma.

Is NCT05820191 still recruiting?

NCT05820191 is currently not yet recruiting. Last updated 20 December 2023.

Last reviewed 2023-12-20 · How we verify

NCT05820191

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

B-amyloid as a Marker for GBM Bioimaging

Not yet recruiting Phase 2 Last updated 20 December 2023

What this trial tests

Phase 2 trial testing Amyvid, Intravenous Solution in Glioblastoma in 3 participants. Not yet recruiting.

Timeline

1 July 2024

Primary endpoint
1 July 2026

1 July 2026

Quick facts

Lead sponsor	Universidad Central del Caribe
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	3
Start date	1 July 2024
Primary completion	1 July 2026
Estimated completion	1 July 2026
Sites	2 locations across Puerto Rico

Drugs / interventions tested

Amyvid, Intravenous Solution — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Universidad Central del Caribe — full company profile →

Who can join

21 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Measurement of Amyvid deposition in GBM tumor structures
Time frame: Through study completion, an average of 1 year
The Amyvid patterns of deposition (brightness or darkness patterns) will be analyzed in whole brain, tumor and peri-tumor resection region with and without representation of post-treatment modifications, as compared to MRI scans.
Correlation of Amyvid deposition with components of high metabolic activity.
Time frame: Through study completion, an average of 1 year
Association of Amyvid deposition patterns with brain tissue components of high and low metabolic activity will be analyzed as compared to MRS images.
Correlation of Amyvid deposition with components of increased vascularization.
Time frame: Through study completion, an average of 1 year
Association of Amyvid deposition patterns with areas of high and low vascularization will be analyzed as compared to MRP scans.

Sponsor's own description

This project is aimed at improvement of glioblastoma (GBM) diagnostic strategies for discrimination of tumor progression and chemo- and radiotherapeutic treatment-related changes in brain tissue. The study will elucidate the diagnostic value of PET imaging with use of amyloid-β radioisotope tracer Amyvid (Florbetapir F18) for GBM. The results of the study will provide data for development of new approach for GBM diagnostics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05820191 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Central del Caribe
Last refreshed: 20 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05820191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing